Johnson & Johnson’s Ethicon has won FDA clearance for airless spray devices to deliver Grifols’ fibrin sealant to stop surgical bleeding, the companies announced today. The Vistaseal fibrin sealant will be the first product Grifols (NSDQ:GRFS) is introducing with Johnson & Johnson (NYSE:JNJ) and Ethicon as part of a global partnership. Get the full story on our […]
FDA’s Gottlieb updates on IV bag shortages after Hurricane Maria
FDA commissioner Dr. Scott Gottlieb expects that the shortage of IV fluids caused by Hurricane Maria in Puerto Rico will improve in the coming weeks and months, according to a statement issued by the agency yesterday. The regulatory chief said that the FDA is working with manufacturers like Baxter (NYSE:BAX) and B. Braun to import products from foreign facilities into the […]
Grifols wins FDA nod for fibrin sealant
Grifols (NSDQ:GRFS) said this week it won FDA approval for its Fibrin Sealant designed for surgical use in adults. The company said the newly cleared product is composed of the plasma proteins fibrinogen and human thrombin. Grifols said that the Fibrin Sealant will be manufactured at its Parts de Vallés facilities in Barcelona, Spain, according to an […]
Grifols posts Q3 sales, earnings gains
Grifols (NSDQ:GRFS) today reported third-quarter sales and earnings growth that nevertheless missed the consensus forecast The Spanish healthcare giant posted profits of €153.9 million , or €0.22 per share, on sales of €1.06 billion for the three months ended Sept. 30 (about $179.3 million, 23¢ and $1.23 billion, respectively). Analysts on Wall Street were looking for earnings of 30¢ […]
Hologic, Grifols close $2B Procleix blood-screening biz sale
Hologic (NSDQ:HOLX) said today that it closed the sale of its stake in the Procleix blood-screening business it runs with Grifols (NSDQ:GRFS) for nearly $1.9 billion. Hologic, which makes the Procleix line, said it dealt its stake for $1.85 billion to Barcelona-based Grifols, which sells the molecular assays and instruments. Blood banks use the products to screen donated blood […]
Grifols pays $51m for minority stake in Access Biologicals
Grifols (NSDQ:GRFS) said today that it paid $51 million for a 49% stake in Access Biologicals, in a deal that includes an option to acquire the rest of the business. That option, for the remaining 51% share in Vista, Calif.-based Access, goes live in 2022, Grifols said. The agreement also includes a provision to supply Access with non-human-use […]
Hologic deals stake in Procleix blood-screening biz to Grifols for $1.9B
Hologic (NSDQ:HOLX) said yesterday that it agreed to deal its stake in the Procleix blood-screening business it runs with Grifols (NSDQ:GRFS) for nearly $1.9 billion. Hologic, which makes the Procleix line, said it’s selling its stake for $1.85 billion to Barcelona-based Grifols, which sells the molecular assays and instruments. Blood banks use the products to screen donated blood for […]
DoJ settles Grifols probe
The U.S. Justice Dept. closed its probe of Grifols (NSDQ:GRFS), according to an SEC filing from the company posted today. The DoJ told the company that it closed its investigation, which concerns “possible violations of the U.S. Foreign Corrupt Practices Act,” Sept. 29, according to the filing. Grifols wrote that in its decision to not prosecute, the DoJ acknowledged […]
Grifols puts up $50m for 20% stake in Singulex
Grifols (NSDQ:GRFS) said today it invested $50 million in clinical diagnostic tech developer Singulex, giving Grifols a 20% stake in the company. Grifols’ investment in Singulex now has a fully-diluted pre-money valuation of $200 million, the company said in an SEC filing. Along with the investment, Grifols will be entitled to appoint a director to serve […]
Grifols puts up $100m for a 49% stake in Interstate Blood Bank
Grifols (NSDQ:GRFS) said today that it agreed to pay $100 million for a 49% stake in plasma collector Interstate Blood Bank. The deal includes an option to buy the remaining 51% for another $100 million and a $10 million call option, Barcelona-based Grifols said. IBB collects blood plasma so that is can be fractionated into blood […]
Cardiac Dimensions taps ex-AccessClosure chief Casciaro for CEO | Personnel Moves
Cardiac Dimensions said this week that it tapped the former chief of AccessClosure, Gregory Casciaro, to be its new president & CEO. Casciaro led AccessClosure until its May 2014 acquisition by Cardinal Health (NYSE:CAH) for $320 million. His résumé includes stints as the chief executive at drug-eluting stent maker Xtent, Orquest (acquired JNJ’s DePuy Acromed in 2003) […]
